# 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

> **NCT04375267** · PHASE1 · COMPLETED · sponsor: **Vastra Gotaland Region** · enrollment: 18 (actual)

## Conditions studied

- Clinical Trial, Phase I
- Neuroendocrine Tumors
- Thymoma
- Mesothelioma

## Interventions

- **DRUG:** 177Lu-DOTA-TATE + olaparib

## Key facts

- **NCT ID:** NCT04375267
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04375267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04375267, "177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04375267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*